Clinical Trial Update: Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial of durvalumab in combination with neoadjuvant chemotherapy for operable urothelial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Urothelial Cancer | Phase 2 | Status: COMPLETED